Update Hepatitis C: Aktuelle Therapieempfehlungen bei Hepatitis C

Literatur

  1. Ferrante JM et al.: Family physicians’ knowledge and screening of chronic hepatitis and liver cancer. Fam Med 2008; 40: 345-51
  2. WHO: Global Hepatitis Report 2017. (www.who.int/hepatitis/publications/global-hepatitisreport2017/ en)
  3. Sarrazin C, Zimmermann T et al.: S3- Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis- C-Virus(HCV)-Infektion. Stand 23. Jänner 2016, AWMF-Register-Nr.: 021/012 (www.awmf.org/leitlinien/ detail/ll/021-012.html)
  4. Tohme RA, Holmberg SD: Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010; 52: 1497-1505
  5. www.hauptverband. at/portal27/hvbportal/content/contentWindow?vie wmode=content&contentid= 10007.733326
  6. Jezequel C et al.: Survival of patients infected by chronic hepatitis c and f0f1 fibrosis at baseline after a 15 years follow-up. J Hepatol 2015; 62: S589
  7. Fachinformation Maviret®
  8. Fachinformation Epclusa®
  9. Fachinformation Zepatier®
  10. Zeuzem S et al.: Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018; 378: 354-69
  11. Puoti M et al.: High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/ pibrentasvir: integrated efficacy analysis of genotype 1-6 patients without cirrhosis. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver, 19.–23. April 2017, Amsterdam
Pfad: